Vladimir Gilca1, Chantal Sauvageau2, Gitika Panicker3, Gaston De Serres2, Manale Ouakki4, Elizabeth R Unger3. 1. Quebec Public Health Institute, Quebec, Canada; Laval University Research Hospital Center, Quebec, Canada. Electronic address: vladimir.gilca@inspq.qc.ca. 2. Quebec Public Health Institute, Quebec, Canada; Laval University Research Hospital Center, Quebec, Canada. 3. Centers for Disease Control and Prevention, Atlanta, USA. 4. Quebec Public Health Institute, Quebec, Canada.
Abstract
BACKGROUND: Limited data is available on the use of different HPV vaccines in the same subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent (9vHPV) and one dose of bivalent vaccine (2vHPV) administered in different order versus two doses of 9vHPV vaccine. METHODS:371 girls and boys aged 9-10 years were randomized (1:1) to receive (I) two doses of 9vHPV or (II) a mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV with a 6 month interval. Antibodies to HPV were tested by ELISA in blood samples collected one or six months post-first dose and one month post-second dose. RESULTS: Post-first dose of 9vHPV 99.4-100% of subjects were seropositive to 9 HPV types included in the vaccine. GMTs varied from 5.0 to 73.6 IU(AU)/ml depending on HPV type. Post-first dose of 2vHPV all subjects were seropositive to HPV16 and 18 (GMTs 16.7 and 11.7 IU/ml, respectively) and 50.0-76.7% were seropositive to 7 types not included in 2vHPV (GMTs varied from 0.3 to 17.5 AU/ml depending on type). Post-second dose all subjects, regardless of the study group, were seropositive to 9 HPV types included in 9vHPV. Anti-HPV16 and 18 GMTs were higher in subjects with the mixed schedule and for the other 7 HPV types higher in subjects who received two doses of 9vHPV vaccine. A higher proportion of subjects who received 2vHPV reported local or systemic adverse events than those who received 9vHPV as the first dose. Post-second dose there were no differences in reported adverse events between the two vaccines. CONCLUSIONS: The results show the mixed HPV vaccination schedules used in this study are immunogenic and have an acceptable safety profile. Although the seroprotective threshold of antibodies remains unknown the 100% seropositivity to all 9 HPV types included in 9vHPV and the increase of GMTs observed in all study groups post-second dose administration are reassuring and suggest protection might be achieved regardless of the schedule used. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov NCT02567955.
RCT Entities:
BACKGROUND: Limited data is available on the use of different HPV vaccines in the same subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent (9vHPV) and one dose of bivalent vaccine (2vHPV) administered in different order versus two doses of 9vHPV vaccine. METHODS: 371 girls and boys aged 9-10 years were randomized (1:1) to receive (I) two doses of 9vHPV or (II) a mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV with a 6 month interval. Antibodies to HPV were tested by ELISA in blood samples collected one or six months post-first dose and one month post-second dose. RESULTS: Post-first dose of 9vHPV 99.4-100% of subjects were seropositive to 9HPV types included in the vaccine. GMTs varied from 5.0 to 73.6 IU(AU)/ml depending on HPV type. Post-first dose of 2vHPV all subjects were seropositive to HPV16 and 18 (GMTs 16.7 and 11.7 IU/ml, respectively) and 50.0-76.7% were seropositive to 7 types not included in 2vHPV (GMTs varied from 0.3 to 17.5 AU/ml depending on type). Post-second dose all subjects, regardless of the study group, were seropositive to 9HPV types included in 9vHPV. Anti-HPV16 and 18 GMTs were higher in subjects with the mixed schedule and for the other 7 HPV types higher in subjects who received two doses of 9vHPV vaccine. A higher proportion of subjects who received 2vHPV reported local or systemic adverse events than those who received 9vHPV as the first dose. Post-second dose there were no differences in reported adverse events between the two vaccines. CONCLUSIONS: The results show the mixed HPV vaccination schedules used in this study are immunogenic and have an acceptable safety profile. Although the seroprotective threshold of antibodies remains unknown the 100% seropositivity to all 9 HPV types included in 9vHPV and the increase of GMTs observed in all study groups post-second dose administration are reassuring and suggest protection might be achieved regardless of the schedule used. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov NCT02567955.
Authors: Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Marie Lebacq; Robbert van der Most; Philippe Moris; Sandra L Giannini; Anne Schuind; Sanjoy K Datta; Dominique Descamps Journal: Hum Vaccin Date: 2011-12-01
Authors: Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt Journal: BMJ Date: 2010-07-20
Authors: Judith F Smith; Michelle Brownlow; Martha Brown; Rose Kowalski; Mark T Esser; Wanda Ruiz; Eliav Barr; Darron R Brown; Janine T Bryan Journal: Hum Vaccin Date: 2007-02-24
Authors: Beatriz Serrano; Laia Alemany; Sara Tous; Laia Bruni; Gary M Clifford; Thomas Weiss; Francesc Xavier Bosch; Silvia de Sanjosé Journal: Infect Agent Cancer Date: 2012-12-29 Impact factor: 2.965
Authors: Aimée R Kreimer; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Mark Schiffman; Paula González; Diane Solomon; Silvia Jiménez; John T Schiller; Douglas R Lowy; Wim Quint; Mark E Sherman; John Schussler; Sholom Wacholder Journal: J Natl Cancer Inst Date: 2011-09-09 Impact factor: 13.506
Authors: Dorota M Gertig; Julia M L Brotherton; Alison C Budd; Kelly Drennan; Genevieve Chappell; A Marion Saville Journal: BMC Med Date: 2013-10-22 Impact factor: 8.775